ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors

ClinicalTrials.gov ID: NCT01736917

Public ClinicalTrials.gov record NCT01736917. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 11:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Study of Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-based Chemotherapy: Hoosier Oncology Group Study QL12-153

Study identification

NCT ID
NCT01736917
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Lawrence Einhorn
Other
Enrollment
65 participants

Conditions and interventions

Interventions

  • 5HT3 Drug
  • Dexamethasone Drug
  • Fosaprepitant Drug

Drug

Eligibility (public fields only)

Age range
15 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2012
Primary completion
Feb 28, 2015
Completion
May 31, 2015
Last update posted
May 24, 2016

2013 – 2015

United States locations

U.S. sites
4
U.S. states
4
U.S. cities
4
Facility City State ZIP Site status
Indiana University Melvin and Bren Simon Cancer Center Indianapolis Indiana 46202
Siteman Cancer Center St Louis Missouri 63110
Nebraska Cancer Specialists Omaha Nebraska 68114
MUSC Hollings Cancer Center Charleston South Carolina 29425

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01736917, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 24, 2016 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01736917 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →